Citation Impact
Citing Papers
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
2003 Standout
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group
2008
Unified Synthesis of Polycyclic Alkaloids by Complementary Carbonyl Activation**
2021 StandoutNobel
Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours
2003
Gastric cancer
2016 Standout
Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome
2007
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
1998
Preclinical and Clinical Pharmacology of Vinca Alkaloids
1992
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
2011 Standout
Platinum-based chemotherapy in metastatic breast cancer: current status
2003
Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles
2004
Enzyme-Catalyzed Activation of Anticancer Prodrugs
2004
Phase I study of oxaliplatin in patients with advanced cancer
1990
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
1997
Fast in vivo imaging of amyloid plaques using μ-MRI Gd-staining combined with ultrasound-induced blood–brain barrier opening
2013
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
1996
Advances in platinum cancer chemotherapy
1988
CH Bond Functionalization: Emerging Synthetic Tools for Natural Products and Pharmaceuticals
2012 Standout
The Risk–Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava
2002 Standout
Drug development from marine natural products
2008 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers
1995
Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates
2001
Basis for effective combination cancer chemotherapy with antimetabolites
2000
Phytotherapy in the treatment of benign prostatic hyperplasia: an update
1999
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects
2005
Engineering the perfect (bacterial) cancer therapy
2010 Standout
Anti-proliferative activity and mechanism of action of titanocene dichloride
1998
New Cisplatin Analogues in Development
1993
Molecular mechanisms of cisplatin resistance
2011 Standout
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer
1992
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
2010 Standout
Novel molecular drug carrier: encapsulation of oxaliplatin in cucurbit[7]uril and its effects on stability and reactivity of the drug
2005
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study
2010
Cellular processing of platinum anticancer drugs
2005 Standout
Circadian clock control of the cellular response to DNA damage
2010 StandoutNobel
Circadian variation inO6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects
2000
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
2008 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
1996
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update
1998
The Cucurbit[n]uril Family
2005 Standout
Tumour-inhibiting platinum complexes—state of the art and future perspectives
2003
Two-stage enzyme mediated drug release from LMWG hydrogels
2005 StandoutNobel
Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data
1989
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Ongoing and unsaid on oxaliplatin: the hope
1998
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity
2007
Sequence- and Region-Specificity of Oxaliplatin Adducts in Naked and Cellular DNA
1998
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
1993
New platinum antitumor complexes
1993
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
New Cisplatin Analogues—On the Way to Better Antitumor Agents
1987
Chemistry of Polyvalent Iodine
2008 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
2009 Standout
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Second-sphere co-ordination of carboplatin and rhodium complexes by cyclodextrins (cyclomalto-oligosaccharides)
1989 StandoutNobel
Organometallic Anticancer Compounds
2010 Standout
Insights into Mechanisms of Cisplatin Resistance and Potential for Its Clinical Reversal
1996
An Efficient, PIFA Mediated Approach to Benzo-, Naphtho-, and Heterocycle-Fused Pyrrolo[2,1-c][1,4]diazepines. An Advantageous Access to the Antitumor Antibiotic DC-81
2005
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
2000
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Current status of trans-platinum compounds in cancer therapy
2001
Additions to Metal-Activated Organonitriles
2002 Standout
Cellular and molecular pharmacology of oxaliplatin.
2002
Occurrence, Biogenesis, and Synthesis of Biologically Active Carbazole Alkaloids
2012 Standout
Genome-Wide Identification of Genes Conferring Resistance to the Anticancer Agents Cisplatin, Oxaliplatin, and Mitomycin C
2004
Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents
2021 StandoutNobel
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
2000
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Antitumor Activity of TZT‐1027, a Novel Doiastatin 10 Derivative
1997
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Advances in Synthetic Applications of Hypervalent Iodine Compounds
2016 Standout
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
2007 Standout
Antitumor Activity, Pharmacology, and Toxicity of Ellipticines, Ellipticinium, and 9-Hydroxy Derivatives: Preliminary Clinical Trials of 2-Methyl-9-Hydroxy Ellipticinium (NSC 264-137)
1980
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Inhibitors of human immunodeficiency virus integrase.
1993 StandoutNobel
General Strategy for the Syntheses of Corynanthe, Tacaman, and Oxindole Alkaloids
2006
Isolation and Synthesis of Biologically Active Carbazole Alkaloids
2002 Standout
The current status of new platinum analogs.
1992
Works of E. Chenu being referenced
Directin vivo observation of 5-fluorouracil release from a prodrug in human tumors heterotransplanted in nude mice: a magnetic resonance study
2000
Morphological and carbogen‐based functional MRI of a chemically induced liver tumor model in mice
2003
A Pygeum africanum extract with so-called phyto-estrogenic action markedly reduces the volume of true and large prostatic hypertrophy
1995
Synthesis and evaluation of antileukemic activity of 5-thienyl- or 5-(2-furyl)-2,3-dihydro-6,7-bis(hydroxymethyl)-1H-pyrrolizine bis(alkylcarbamates) and derivatives
1989
Antitumor activity of l-OHP in mice
1985
Experimental in vivo cross-resistance of vinca alkaloid drugs
1981
Cytostatic action of two nitrosoureas derived from cysteamine
1986
Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
1989
Synthèse partielle et propriétés oncostatiques des pseudo‐tubulosines, analogues de l'émétine et de la tubulosine
1980
Direct in vivo observation of 5‐fluorouracil release from a prodrug in human tumors heterotransplanted in nude mice: a magnetic resonance study
2000
Experimental antitumor activity of 5′-nor-anhydrovinblastine navelbine
1984
Methoxy-9-ellipticine lactate. I. Experimental study (oncostatic and immunosuppressive actions; preclinical pharmacology).
1970